Login to Your Account



Financings Roundup

Anthera Raises $33M After Stock Bump on Lupus Data

By Staff Reports


Monday, July 23, 2012
After getting hammered a month ago on news of a missed primary endpoint in the Phase IIb PEARL-SC study of lupus drug blisibimod, shares of Anthera Pharmaceuticals Inc. rebounded last week when the Hayward, Calif.-based firm released promising data from a subset of patients in the study.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription